Drugs / Cytotoxic T lymphocytes (CTLs)
Cytotoxic T lymphocytes (CTLs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01923766 | Sep 2013 → Mar 2020 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Children's National Research Institute | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytotoxic T lymphocytes (CTLs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01923766 ↗ |
| Known as | m-CTL | “These cells have been trained to attack adenovirus/EBV/CMV- infected cells and are called multivirus-specific cytotoxic (killer) T-cells or "m-CTL."” NCT01923766 ↗ |
| Known as | multivirus-specific cytotoxic (killer) T-cells | “These cells have been trained to attack adenovirus/EBV/CMV- infected cells and are called multivirus-specific cytotoxic (killer) T-cells or "m-CTL."” NCT01923766 ↗ |
| Action | Deplete | “T lymphocytes can kill viral cells” NCT01923766 ↗ |
| Modality | Cell therapy | “These cells have been trained to attack adenovirus/EBV/CMV- infected cells and are called multivirus-specific cytotoxic (killer) T-cells or "m-CTL."” NCT01923766 ↗ |
| Route | Intravenous | “will be given by slow intravenous injection over 1-2 minutes” NCT01923766 ↗ |